Is Pazopanib a targeted drug? Which generation

Pazopanib (Pazopanib) developed by GlaxoSmithKline is an oral, second-generation, multi-target tyrosine kinase inhibitor The agent is a second-generation targeted therapy drug that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor and c-kit, which are key proteins responsible for tumor growth and survival.

Pazopanib exhibits promising potency in vitro against all humanVEGFRs and closely related tyrosine receptor kinases, and antitumor activity in several human tumor xenografts, including renal cell carcinoma (RCC) andsoft tissue sarcoma. In Phase I and II clinical trials, pazopanib was generally well tolerated, with the main side effects being hypertension, fatigue, or gastrointestinal disturbances. Pazopanib alone can reduce tumor size and stabilize disease in a large number of patients. Pazopanib monotherapy is being evaluated in a Phase III trial in patients with RCC and as combination therapy with lapatinib in patients with breast cancer.

The original drug pazopanib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be around 3,000 yuan. The price of pazopanib's original drug, 200mg*30 tablets, per box sold overseas may be around RMB 1,000 (the price may fluctuate due to exchange rates). There are also generic pazopanib drugs produced in other countries. The price of a box of 200mg*30 tablets produced by a Bangladeshi pharmaceutical factory may be around 500 yuan (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.